Search Results for: ALBUMIN MARKET Global Human Albumin
Articles
ALBUMIN MARKET - Global Human Albumin Market: Extra Revenues to Come Through Non-Therapeutic Applications November 18, 2015
Aish Vivekanandan, Frost & Sullivan Analyst, reports that human albumin is widely considered as a plasma replacement or expander for therapeutic purposes. However, for over a decade, the healthcare industry has been exploring the use of human albumin as a non-therapeutic substance/excipient for commercial settings.
Dyadic Announces Research & Development Collaboration Agreement With Global Biopharmaceutical Company February 6, 2024
Dyadic International, Inc. recently announced it has signed a fully funded evaluation agreement including commercial option with an undisclosed leading...BeiGene Initiates Global Phase 3 Trial of Anti-PD-1 Antibody January 8, 2018
BeiGene, Ltd. recently announced that in December 2017, the first patient was dosed in a global Phase 3 clinical trial...DRUG DEVICE MARKET - Joining Forces: Global Markets for Drug-Device Combinations November 19, 2015
Kevin James and Kevin Gainer of BCC Research indicate the development of the market for combination products is closely related to the drug delivery systems sector, which represents a vast area of research and the demand for sophisticated drug delivery devices behind many novel product developments.
Novozymes’s Recombinant Human Albumin Helps Innovative Dry Eye Therapy May 24, 2013
Novozymes Biopharma recently announced that an ophthalmic solution made using its recombinant human albumin, has been approved for Phase I/II...Novozymes Biopharma's rAlbumin Approved in Japan February 28, 2013
Novozymes Biopharma has recently announced that one of its leading customers has achieved approval of a medical device in...Novozymes Biopharma Aligns Recombinant Human Albumin Portfolio January 14, 2013
Novozymes Biopharma recently announced the introduction of a new brand and visual identity for its recombinant human albumin (rAlbumin)...Novozymes' rAlbumin Supports Faster Time-to-Market for Neomend Adhesion Barrier Sealant May 6, 2012
Novozymes Biopharma recently announced that its recombinant human albumin (rAlbumin), Albucult, is being used by Neomend in the company's Progel...SPECIAL FEATURE - Excipients: Advanced Biologics Require Innovative Excipient Science March 29, 2024
Contributor Cindy H. Dubin speaks with several leading companies to discuss novel and functional excipients being developed, the role they will play in reformulations and new formulations, and their versatility in drug delivery.
SPECIAL FEATURE - Improving Bioavailability & Solubility: The Never-Ending Quest February 29, 2024
Contributor Cindy H. Dubin speaks with several companies to review their innovative technologies in this annual report on bioavailability and solubility.
MoonLake Immunotherapeutics Announces Positive Feedback From FDA & EMA on Regulatory Path for Phase 3 Program February 26, 2024
MoonLake Immunotherapeutics recently announced the successful outcome of its end-of-Phase 2 interactions with the US FDA as well as positive...MoonLake Immunotherapeutics Achieves Landmark Milestone With Positive Phase 2 Results for Nanobody Sonelokimab in Hidradenitis Suppurativa June 26, 2023
MoonLake Immunotherapeutics recently announced positive top-line results from its global Phase 2 MIRA trial evaluating the efficacy and safety of the Nanobody sonelokimab in patients with moderate-to-severe….
Avacta Group Announces Achievement of Preclinical Development Milestone in LG Chem Life Sciences Partnership October 5, 2021
Avacta Group plc recently announced a preclinical development milestone has been achieved in the multi-target therapeutics development partnership with LG Chem Life Sciences, the life sciences division of the South Korean LG Group, triggering an….
DRUG DELIVERY - CAPRO(TM): A New Advance in Polymeric Drug Delivery October 4, 2021
Bob Wieden and Chun Wang, PhD, discuss how significant challenges, coupled with the complexity and diversity of new pharmaceuticals, have fueled the development of a novel polymeric drug delivery platform that overcomes a great many bioavailability and delivery obstacles.
SPECIAL FEATURE - Outsourcing Formulation Development & Manufacturing: Meeting Demand for Biologics & Specialty Drugs June 2, 2021
Contributor Cindy Dubin highlights the formulation development and manufacturing offerings from some of the leading CDMOs to address a myriad of challenges – from complex compounds to poor solubility to dual-release profiles.
SPECIAL FEATURE - Improving Bioavailability & Solubility: Each Molecule Is Unique March 1, 2021
Contributor Cindy H. Dubin speaks with several innovative companies to discuss novel approaches to improving bioavailability and solubility that have one commonality: they treat each molecule as an individual.
BioAtla & BeiGene Form Worldwide Development & Commercialization Collaboration April 9, 2019
BioAtla , LLC and BeiGene, Ltd. recently announced the two companies have entered into a global co-development and collaboration agreement for the development, manufacturing, and commercialization of BioAtla’s investigational CAB CTLA-4 antibody (BA3071).
Bayer Receives FDA Approval of myBETAapp & BETACONNECT Navigator June 6, 2017
Bayer recently announced that the US FDA has approved a supplemental Biologics License Application (sBLA) for myBETAapp and the BETACONNECT...Hebei Changshan Biochem Pharma & Albumedix Enter Development Agreement May 20, 2016
Albumedix and Hebei Changshan Biochem Pharma Co. recently announced they have entered into a supply agreement for the development of...DIAGNOSTIC TESTING - Diabetes Diagnostic Testing: A Move From Invasive to Non-Invasive Testing November 19, 2015
Divyaa Ravishankar, Frost & Sullivan Analyst, focuses on the innovations around self-monitoring glucose meters and continuous glucose monitoring devices, providing in-depth competitive intelligence on some of the technologies and non-invasive techniques.
Issues
November / December 2012
COVER CONTRACT SERVICES – Industry Trends: Outsourcing Pharmaceutical Development & Innovation Frost & Sullivan Analysts Winny Tan, PhD, and Jennifer...
